- Home
- PRLB vs WGS Comparison
PRLB vs WGS Comparison
Compare PRLB & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLB
- WGS
- Stock Information
- Founded
- PRLB 1999
- WGS 2017
- Country
- PRLB United States
- WGS United States
- Employees
- PRLB N/A
- WGS N/A
- Industry
- PRLB Metal Fabrications
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- PRLB Industrials
- WGS Technology
- Exchange
- PRLB Nasdaq
- WGS Nasdaq
- Market Cap
- PRLB 713.9M
- WGS 1.1B
- IPO Year
- PRLB 2012
- WGS N/A
- Fundamental
- Price
- PRLB $29.17
- WGS $56.00
- Analyst Decision
- PRLB Buy
- WGS Strong Buy
- Analyst Count
- PRLB 4
- WGS 5
- Target Price
- PRLB $41.00
- WGS $45.80
- AVG Volume (30 Days)
- PRLB 263.3K
- WGS 603.9K
- Earning Date
- PRLB 11-01-2024
- WGS 10-29-2024
- Dividend Yield
- PRLB N/A
- WGS N/A
- EPS Growth
- PRLB N/A
- WGS N/A
- EPS
- PRLB 0.96
- WGS N/A
- Revenue
- PRLB $509,274,000.00
- WGS $243,657,000.00
- Revenue This Year
- PRLB $0.18
- WGS $31.32
- Revenue Next Year
- PRLB $3.64
- WGS $14.29
- P/E Ratio
- PRLB $30.48
- WGS N/A
- Revenue Growth
- PRLB 4.91
- WGS 3.06
- 52 Week Low
- PRLB $23.01
- WGS $1.16
- 52 Week High
- PRLB $41.87
- WGS $61.89
- Technical
- Relative Strength Index (RSI)
- PRLB 52.97
- WGS 68.08
- Support Level
- PRLB $27.67
- WGS $51.04
- Resistance Level
- PRLB $29.55
- WGS $61.41
- Average True Range (ATR)
- PRLB 0.72
- WGS 3.77
- MACD
- PRLB 0.12
- WGS 0.70
- Stochastic Oscillator
- PRLB 76.38
- WGS 72.59
About PRLB Proto Labs Inc. Common stock
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. The majority of its revenue is derived from the United States of America.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.